KIRKLAND, QC, Jan. 3, 2019 /CNW Telbec/ - Valeo Pharma Inc., (the "Corporation") a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products, is pleased to announce that it has received a receipt from the Autorité des marchés financiers for the filing of its final non-offering long form prospectus on December 27, 2018. A copy of the prospectus is available under the Corporation's profile on SEDAR (www.sedar.com). The Corporation is also pleased to announce that it has applied for listing of its Class "A" shares ("Shares") on the Canadian Securities Exchange (the "CSE") ". Listing of the Shares will be subject to the Corporation fulfilling all of the listing requirements of the CSE, including the receipt by the CSE of all final documentation.
About Valeo Pharma
Valeo Pharma is a specialty pharmaceutical company dedicated to the approval and launch of innovative prescription products in Canada. With a focus on neurodegenerative diseases, woman's health and rare diseases, Valeo Pharma has a growing portfolio of innovative products and a platform to properly manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all capabilities internally to register and market health care solutions for Canadian patients. For more information, please visit www.valeopharma.com.
SOURCE Valeo Pharma inc.
For further information: Steve Saviuk - President and CEO, Phone : 514 693-8830, Email : [email protected]